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Vitiligo is an acquired idiopathic hypomelanotic disorder characterized by circumscribed depigmented macules
resulting from the loss of cutaneous melanocytes. Although the exact cause of vitiligo remains obscure,
autoimmunity may play a role in the development of the disease. The present study was undertaken to
investigate the applicability of phage display technology to identify B-cell autoantigens in vitiligo. A melanocyte
cDNA phage display library was subjected to rounds of enrichment with vitiligo patient IgG. Subsequently,
enriched IgG-binding peptides representing putative autoantigens were identified by sequencing their
encoding cDNAs. Radioimmunoassays were used to confirm the immunoreactivity of vitiligo patient (n¼ 61)
and control (n¼ 28) sera to several of the putative autoantigens. Non-segmental vitiligo patient sera (n¼ 53)
were positive for antibody (Ab) reactivity to gamma-enolase (8%); alpha-enolase (9%); heat-shock protein 90
(13%); osteopontin (4%); ubiquitin-conjugating enzyme (15%); translation-initiation factor 2 (6%); and GTP-
binding protein, Rab38 (15%). Ab reactivity to at least one of the previously unknown autoantigens was detected
in 51% of patients with non-segmental vitiligo. In contrast, Ab reactivity in a group of patients with segmental
vitiligo (n¼ 8) was not demonstrated. Overall, the study indicated that the targets of autoantibodies in vitiligo
patients can be revealed by employing the methodology of phage display.
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INTRODUCTION
Vitiligo is an acquired idiopathic hypomelanotic disorder
characterized by circumscribed depigmented macules result-
ing from the loss of cutaneous melanocytes. Two major
clinical subtypes are distinguished, namely, segmental
vitiligo, which follows dermatomal lines, and non-segmental
(generalized) vitiligo, which includes symmetrical and
acrofacial manifestations of the disease (Taieb, 2000).
Although the exact cause of vitiligo remains to be established,
autoimmunity has been suggested to play a role in the
development of the disease, as it is frequently associated with
autoimmune disorders (Alkhateeb et al., 2003). Furthermore,
autoantibodies (Naughton et al., 1983) and autoreactive
T lymphocytes (Ogg et al., 1998; Lang et al., 2001; Palermo
et al., 2001; Van den Boorn et al., 2009) that target pigment
cells have been detected in patients with vitiligo. Several
genes that have a role in regulating the immune response
have been associated with susceptibility to vitiligo, including
AIS1, AIS2, AIS3, NALP1, and PTPN22, and certain antigen
(Ag) specificities of the major histocompatibility complex
(Spritz, 2007). In addition to the autoimmune hypothesis, the
theory that metabolic dysregulation can lead to the produc-
tion of toxic metabolites that damage melanocytes with
resultant vitiligo is well documented (Schallreuter et al.,
2005; Dell’Anna and Picardo, 2006). Notably, in vitro studies
have provided a link and a temporal sequence connecting
cellular oxidative stress and the immune response in vitiligo:
stressed melanocytes were found to mediate dendritic
cell activation with the consequent dendritic cell effector
functions having a role in the destruction of pigment cells
(Kroll et al., 2005). Conceivably, autoimmune responses may
arise as a secondary phenomenon following melanocyte
destruction with aberrant immune reactivities then amplify-
ing the damage to pigment cells.
The role of autoantibodies in the destruction of melano-
cytes in vitiligo is uncertain, although vitiligo-associated
autoantibodies are able to destroy melanocytes in vitro by
complement-mediated damage and antibody (Ab)-dependent
cellular cytotoxicty, and in vivo after passive immunization of
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nude mice grafted with human skin (Norris et al., 1988;
Gilhar et al., 1995). Studies have revealed that autoantibodies
in vitiligo patients are commonly directed against pigment
cell Ags that are located on the surface of the cell, although
these remain unidentified (Cui et al., 1992). In addition,
specific vitiligo-associated autoantigens have been identified,
including tyrosinase (Song et al., 1994), tyrosinase-related
protein-1 (Kemp et al., 1998a), tyrosinase-related protein-2
(Okamoto et al., 1998), Pmel17 (Kemp et al., 1998b),
transcription factor SOX10 (Hedstrand et al., 2001), and the
melanin-concentrating hormone receptor 1 (Kemp et al.,
2002). Although Abs to pigment cells may not be the direct
etiological agents of vitiligo, further studies of anti-melano-
cyte Ab reactivity are particularly valuable as they may reveal
autoantigens that are important for pathological T-cell
responses in vitiligo patients (Ogg et al., 1998; Lang et al.,
2001; Palermo et al., 2001; Van den Boorn et al., 2009).
The aim of the present study was to identify vitiligo-
associated autoantigens using the phage display technique
based on the pJuFo cDNA expression system (Crameri and
Suter, 1993). This methodology permits both the expression
of cDNA libraries and the covalent attachment of the
expressed products as fusion proteins on the surface of
filamentous phage particles, thus allowing the selective
enrichment of phage particles that display IgG-binding
peptides in rounds of biopanning with patient IgG samples.
RESULTS
Enrichment of phage particles displaying IgG-binding peptides
by vitiligo patient IgG
A melanocyte cDNA phage display library was subjected to
five rounds of biopanning (Figure 1) against a pool of
biotinylated IgG. Each of the 10 IgG samples included in the
pool was prepared from an individual vitiligo patient selected
from a cohort of patients who had no other autoimmune
disease (Table 1). After each round of enrichment, the
number of phage particles eluted was estimated by infecting
Escherichia coli XL1-Blue (Stratagene, La Jolla, CA) and
plating on a selective medium. A 20-fold increase in the ratio
of phage particles eluted to the phage particles applied for
enrichment was noted after the fifth round of biopanning
indicating enrichment of the phage display library (Table 2).
There was no significant change in the range of insert sizes
from the multiple rounds of enrichment (Table 2), suggesting
that there was no apparent negative selection on the basis of
size constraints of the cDNAs.
Identification of IgG-binding proteins enriched by vitiligo
patient IgG
After the fifth round of enrichment, 60 randomly chosen
individual clones were grown, phagemid DNA isolated from
each culture, and this analyzed by polymerase chain reaction
(PCR) amplification with 1192 and 1500 primers. The PCR
amplification products were purified and sequenced to
identify cDNA inserts by BLAST searches of international
databases. Of the 60 clones sequenced, 28 cDNAs encoded
proteins of known function (Table 3) and 10 encoded proteins
with undetermined functions (data not shown). All proteins
were in-frame with pJuFo-Sfi-encoded Fos peptide that would
allow for expression and display on phage particles. Of the
remainder, 16 cDNAs encoded proteins of known or
undetermined function that were not in-frame for expression
and display on phage particles, 4 clones had no significant
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Figure 1. Enrichment of the melanocyte cDNA phage display library with
vitiligo patient IgG. The melanocyte cDNA phage display library was
incubated with biotinylated vitiligo patient IgG. The phage–antigen–IgG
complexes were captured on Dynabeads M-280 Streptavidin. Non-
specifically bound and unbound phage particles were removed by washing.
IgG-bound phage particles were eluted and used to infect E. coli XL1-Blue
and amplified for use in further rounds of selection.
Table 1. Characteristics of patients from whom IgG
was used for selective enrichment of the melanocyte
cDNA phage display library
Patient1 Sex
Age
(years)
Disease
duration
(years) Vitiligo type
V1 F 52 6 Symmetrical
V2 F 40 9 Symmetrical and periorificial
V3 F 54 33 Symmetrical and periorificial
V4 M 77 7 Symmetrical and periorificial
V5 F 43 12 Symmetrical
V6 M 23 1 Periorificial
V7 F 58 4 Segmental
V8 F 37 27 Symmetrical with segmental patch
V13 M 68 10 Symmetrical and periorificial
V17 F 70 o1 Symmetrical
F, female; M, male; MCHR1, melanin-concentrating hormone receptor 1;
TRP, tyrosinase-related protein.
1No patient had clinical manifestations of any other autoimmune disease.
All patients were negative for autoantibodies to tyrosinase (Kemp et al.,
1997a), TRP-1 (Kemp et al., 1998a), TRP-2 (Kemp et al., 1997b), Pmel17
(Kemp et al., 1998b), MCHR1 (Kemp et al., 2002), and SOX10 (Hedstrand
et al., 2001), except patient V7 who was weakly positive for tyrosinase
autoantibodies (Kemp et al., 1997a), and patients V6 and V13 who were
positive for MCHR1 autoantibodies (Kemp et al., 2002).
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matches, and 2 clones did not contain a cDNA insert (data
not shown). More than one copy of several putative Ags was
present in the final selected library (Table 3), a further
indication that the biopanning process with vitiligo patient
IgG had enriched the phage display library with Ab-binding
peptides.
Seven potential autoantigens enriched from the bio-
panning procedure were chosen for further analysis in
Table 2. Analysis of rounds of biopanning of the melanocyte cDNA phage display library with vitiligo patient IgG
Round
Phage applied
(cfu)
Phage eluted
(cfu)
Ratio phage
eluted:phage applied
(E:A)
Fold increase in
ratio of E:A1
Recombinant
phage (%)
Size range of cDNA
inserts (bp)
1 1.3 1011 7.2 103 5.5 108 1.0 19/24 (79%) 1000–2300
2 3.3 1010 1.2 103 3.6 108 0.7 19/24 (79%) 1000–2500
3 2.3 1010 1.0 103 4.4 108 0.8 20/24 (83%) 800–2500
4 1.8 1010 8.4 103 4.8 107 8.8 21/24 (88%) 800–2500
5 1.8 1010 20.9103 1.1 106 20.7 20/24 (83%) 800–2500
cfu, colony-forming unit
1The ratios of E:A phage are normalized against the ratio of E:A phage in the first round of biopanning.
Table 3. Enriched cDNA-encoded proteins with known function isolated from biopanning of the melanoctye cDNA
phage display library with vitiligo patient IgG
Protein identity
Accession
number
No. of
clones1
First amino
acid2 Previously reported as an autoantigen
Ubiquitin-conjugating enzyme BC000468 2/60 1 No
Translation-elongation factor 6 NM002212 2/60 1 No
Osteopontin XM011125 2/60 1 Type I diabetes mellitus (Fierabracci et al., 1999); Rheumatoid
arthritis (Sakata et al., 2001)
Translation-elongation factor 1
alpha
NM005348 2/60 1 Systemic lupus erythematosus (Frampton et al., 2000); Atopic
dermatitis (Ohkouchi et al., 1999)
Heat-shock protein 90 NM005348 1/60
2/60
206
71
Systemic lupus erythematosus (Conroy et al., 1994); Melanoma
with melanoma-associated hypopigmentation (Kiniwa et al., 2001)
Alpha-enolase BC004458 1/60 20 Systemic lupus erythematosus (Pratesi et al., 2000); Premature
ovarian failure (Sundblad et al., 2006)
Gamma-enolase BC002745 1/60
1/60
1
23
Systemic lupus erythematosus (Pratesi et al., 2000)
SAR1 gene homolog A (GTPase) BC003658 1/60 1 No
Melanin-concentrating hormone
receptor 1
NM005297 1/60 1 Vitiligo (Kemp et al., 2002)
Ribosomal protein L9 NM000661 2/60 1 No
Ribosomal protein L24 NM145729 1/60 1 No
Translation-initiation factor 2 BC002513 1/60 1 Melanoma with melanoma-associated hypopigmentation (Kiniwa
et al., 2001)
GTP-binding protein Rab38 NM022377 2/60 1 Melanoma (Zippelius et al., 2007)
Ribosomal protein S18B NM014046 2/60 1 Colorectal cancer (Somers et al., 2002)
Tyrosine hydroxylase NM199292 1/60 214 Autoimmune polyglandular syndrome type 1 (Hedstrand et al.,
2000)
Triosphosphate isomerase 1 NM000365 1/60 1 No
Integrin beta 4 NM000213 1/60 1 No
Ribosomal RNA processing
protein
BC020641 1/60 1 No
1Number of clones representing the identified cDNA sequence.
2The first amino acid of the identified cDNA coded for in the clone. The ATG start codon of the identified cDNA is designated as encoding amino acid
residue number 1.
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radioimmunoassays to determine Ab reactivity in a panel of
vitiligo patient sera. These included alpha-enolase, gamma-
enolase, osteopontin, and heat-shock protein (HSP) 90, all of
which had been identified as the targets of autoantibodies in
autoimmune disease (Table 3), and translation-initiation
factor 2 and GTP-binding protein, Rab38, previously reported
as autoantigens in melanoma (Table 3). Putative autoantigens
having specific expression and function in pigment cells were
GTP-binding protein, Rab38, and ubiquitin-conjugating
enzyme (UCE) (Table 3), and these were therefore analyzed
further. The cDNA encoding each putative autoantigen was
cloned into pcDNA3 using Ag-specific primers (Supplemen-
tary Table S1), as described in Materials and Methods.
Results of radioimmunoassays with vitiligo patient and control
sera
Plasmids containing putative autoantigen-encoding cDNAs
(Supplementary Table S1) were translated in vitro, as detailed
in Materials and Methods, to provide radiolabelled proteins.
Sera from 61 vitiligo patients and 28 healthy controls were
then tested for immunoreactivity to each putative autoantigen
in radioimmunoassays. For each serum, an Ab index was
assigned, this being the mean Ab index of at least two
experiments (SD of o10%) (Figure 2). The upper limit of
normal for each assay was calculated using the mean Ab
indexþ 3SD of the population of 28 healthy individuals
(Figure 2). Any serum with an Ab index above the upper limit
of normal was designated as positive for Ab reactivity.
The results of the radioimmunoassay are summarized in
Table 4. Sera from 28 controls were negative for Abs to all the
Ags tested, except for two individuals who had immuno-
reactivity to HSP90 and alpha-enolase in one case, and to
HSP90 and osteopontin in the second case (Table 4). No
patient with segmental vitiligo was positive for Abs to any of
the autoantigens analyzed (Table 4). In the patients with non-
segmental vitiligo, Ab reactivity to the individual Ags ranged
from 6 to 15% of the total patients tested (Table 4). In
addition, Ab responses to the individual Ags in patients with
and without an autoimmune disease, ranged from 0 to 38 and
3 to 18%, respectively (Table 4).
A significant difference in the prevalence of Abs in the
control and non-segmental vitiligo patient groups was noted
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Figure 2. Antibody (Ab) indices of vitiligo patient and control sera in
radioimmunoassays. Non-segmental vitiligo patient (n¼53), segmental
vitiligo patient (n¼8) and control (n¼ 28) sera were analyzed in
radioimmunoassays for Ab reactivity to gamma-enolase, alpha-enolase,
HSP90, osteopontin, ubiquitin-conjugating enzyme (UCE), translation-
initiation factor 2 (TIF2), and GTP-binding protein, Rab38, as detailed in
Materials and Methods. The Ab index shown for each serum sample is the
mean of at least two experiments. The upper limits of normal for each
radioimmunoassay were Ab indices of gamma-enolase, 1.30; alpha-enolase,
1.40; HSP90, 1.59; osteopontin, 1.38; UCE, 1.22; TIF2, 1.23; GTP-binding
protein, Rab38, 1.64. S, symmetrical vitiligo patients; Seg, segmental vitiligo
patients; C, healthy controls.
Table 4. Immunoreactivity of vitiligo patient and control sera to putative autoantigens
Antigen
Controls1
(n=28)
Non-
segmental
vitiligo1
(n=53)
P-
value2
Segmental
vitiligo1
(n=8)
P-
value2
Non-segmental
vitiligo without
autoimmune
disease1 (n=40)
P-
value2
Non-segmental
vitiligo with
autoimmune
disease1 (n=13)
P-
value2
P-
value3
Gamma-enolase 0 (0) 4 (8) 0.29 0 (0) — 3 (8) 0.27 1 (8) 0.32 1.00
Alpha-enolase 1 (4) 5 (9) 0.66 0 (0) 1.00 1 (3) 1.00 4 (31) 0.03 0.01
HSP90 2 (7) 7 (13) 0.49 0 (0) 1.00 2 (5) 1.00 5 (38) 0.02 0.01
Osteopontin 1 (4) 5 (9) 0.66 0 (0) 1.00 1 (3) 1.00 4 (31) 0.03 0.01
Ubiquitin-conjugating enzyme 0 (0) 8 (15) 0.04 0 (0) — 7 (18) 0.04 1 (8) 0.32 0.66
Translation-initiation factor 2 0 (0) 3 (6) 0.55 0 (0) — 3 (8) 0.26 0 (0) — —
GTP-binding protein Rab38 0 (0) 8 (15) 0.04 0 (0) — 7 (18) 0.04 1 (8) 0.32 0.66
1The number of antibody-positive sera with percentage in parentheses.
2P-value calculated using Fisher’s exact test for comparing the prevalence of antibodies in vitiligo patient and in control groups. Po0.05 was considered
significant.
3P-value calculated using Fisher’s exact test for comparing the prevalence of antibodies in non-segmental vitiligo (with or without autoimmune disease)
patient groups. Po0.05 was considered significant.
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only for anti-UCE and anti-GTP-binding protein, Rab38, Abs
(Table 4). In the cohort of patients with non-segmental
vitiligo, but no autoimmune disease, a significant difference
from the controls was apparent again only in the case of the
prevalence of Abs against anti-UCE and anti-GTP-binding
protein, Rab38, Abs (Table 4). A significant difference in the
prevalence of Abs in patients with non-segmental vitiligo and
with autoimmune disease when compared with both the
controls and the non-segmental vitiligo (without autoimmune
disease) patient group was noted for alpha-enolase, HSP90,
and osteopontin (Table 4).
Analysis of Ab reactivity to the identified autoantigens in vitiligo
patients
An overall analysis of Ab reactivity to the identified
autoantigens in the vitiligo patient and control groups is
shown in Table 5. Ab reactivity to at least one of the reported
autoantigens was detected in 27 of 53 (51%) patients with
non-segmental vitiligo, but in only 2 of 28 (7%) controls and
in 0 of 8 (0%) patients with segmental vitiligo. In the non-
segmental patient groups with and without autoimmune
disease, humoral immune responses to the analyzed auto-
antigens were demonstrated in 10 of 13 (77%) and in 17 of 40
(43%) individuals tested, respectively.
A significant difference in the prevalence of immuno-
reactivity in the controls and patients was evident only in the
non-segmental vitiligo patient group (Table 5). The preva-
lence of Ab reactivity was also increased significantly in the
non-segmental vitiligo patient groups (with or without
autoimmune disease) when compared with controls (Table 5).
No significant difference was apparent when comparing the
non-segmental vitiligo patient groups with or without
autoimmune disease (Table 5).
The details of the 27 non-segmental vitiligo patients who
were positive for Ab reactivity to the identified autoantigens
are summarized in Table 6. A total of 14 and 13 patients
showed humoral immune responses to one and to two Ags,
respectively (Table 6). In addition, in the 17 patients without
an autoimmune disease, 10 and 7 had immunoreactivity to 1
and to 2 Ags, respectively, whereas in the 10 patients with an
autoimmune disorder, 4 and 6 had Ab targeted against 1 and
2 Ags, respectively (Table 6). The majority of Abs against
alpha-enolase, HSP90, and osteopontin were identified in
non-segmental vitiligo patients with autoimmune disease
with 13/17 of the detected reactivities (Table 6). In contrast,
the majority of Abs to UCE, translation-initiation factor 2,
GTP-binding protein, Rab38, were revealed as targets of the
humoral immune response in non-segmental vitiligo patients
without an autoimmune disorder with 17/19 of the detected
reactivities (Table 6).
For comparison, the details of the 26 non-segmental
vitiligo patients who were negative for Ab reactivity to the
autoantigens identified in this study are given in Table 7.
These details are compared with those of patients positive for
Ab responses in Table 8. There was no apparent correlation
between the detection of autoantibodies to the reported
autoantigens and either disease duration, the age of disease
onset, or the clinical sub-type of non-segmental vitiligo
(Table 8). In addition, a correlation was not evident between
the extent and/or activity of vitiligo and the number of
autoantibodies detected. The prevalence of autoimmune
disorders and of Abs to the melanin-concentrating hormone
receptor 1 was increased in the group of patients with
immunoreactivity to the identified autoantibody targets
(Table 8).
DISCUSSION
The combination of affinity selection and biological ampli-
fication employed in phage display technology makes it a
particularly useful technique for the isolation of previously
unknown autoantigens. Large cDNA libraries can be
screened in a single experiment, and even if their expression
in the original library is rare, IgG-binding peptides can be
identified through repeated rounds of enrichment. Further-
more, displayed proteins may assume their native structure
(Skerra and Pluckthun, 1988), and the libraries are screened
in liquid-phase in contrast to conventional immunoscreening
on nitrocellulose membranes. Both these attributes are
important for detecting Ab binding to conformational rather
than linear epitopes. In this study, the technique of phage
display based on the pJuFo cDNA expression system (Crameri
and Suter, 1993) was employed to identify melanocyte
autoantigens in vitiligo.
Several putative autoantigens were enriched from the
melanocyte cDNA phage display library by their ability to
bind to IgG from vitiligo patients. Four of the autoantibody
Table 5. Analysis of antibody reactivity to the identified autoantigens in vitiligo patients and controls
Antibody
reactivity
Controls
(n=28)
Non-
segmental
vitiligo
(n=53) P-value1
Segmental
vitiligo
(n=8) P-value1
Non-segmental
vitiligo without
autoimmune disease
(n=40) P-value1
Non-segmental
vitiligo with
autoimmune disease
(n=13) P-value1 P-value2
Negative 26 (93%) 26 (49%) o0.0001 8 (100%) 1.00 23 (58%) 0.002 3 (23%) o0.0001 0.06
Positive 2 (7%) 27 (51%) 0 (0%) 17 (43%) 10 (77%)
1P-value calculated using Fisher’s exact test for comparing the prevalence of antibody reactivity in vitiligo patient and control groups. Po0.05 was
considered significant.
2P-value calculated using Fisher’s exact test for comparing the prevalence of antibodies in non-segmental vitiligo (with or without autoimmune disease)
patient groups. Po0.05 was considered significant.
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targets analyzed, namely, alpha-enolase, gamma-enolase,
osteopontin, and HSP90, have been defined as autoantigens
in several autoimmune diseases (Conroy et al., 1994;
Fierabracci et al., 1999; Pratesi et al., 2000; Sakata et al.,
2001; Sundblad et al., 2006); hence they are likely to be
markers of autoimmunity, but not specific to vitiligo. Indeed,
the majority of vitiligo patients with Ab reactivity to alpha-
enolase, osteopontin, and HSP90 also had an autoimmune
disorder. Interestingly, autoantibody responses to HSP70 and
HSP90 have been detected in a single melanoma patient with
concurrent melanoma-associated hypopigmentation (Kiniwa
et al., 2001), and recent studies have demonstrated the
release of HSP70 from stressed melanocytes (Denman et al.,
2008). The anti-HSP Abs found in some vitiligo patients may
therefore result from an immune response to extracellular
HSPs.
Translation-initiation factor 2 has been reported as an
autoantigen in a single melanoma patient with concurrent
melanoma-associated hypopigmentation (Kiniwa et al.,
2001). Abs to this protein were detected at a low frequency
in only 3 of 53 (6%) non-segmental vitiligo patients.
The reason for the autoantigenicity of this protein
remains undetermined, but other translation–initiation and
translation–elongation factors have been reported as auto-
antigens in other conditions (Ohkouchi et al., 1999;
Frampton et al., 2000; Kiniwa et al., 2001).
Table 6. Details of non-segmental vitiligo patients with antibody reactivity to the identified autoantigens
Antibody reactivity Patient details
Patient
Gamma-
enolase
Alpha-
enolase HSP90 Osteopontin
Ubiquitin-
conjugating
enzyme
Translation-
initiation
factor 2
GTP-binding
protein
Rab38
Vitiligo
type
Autoimmune
disease1
Age at vitiligo
onset (years)
Disease
duration
(years)
MCHR1
antibodies2
V1 (F) + +      S  46 6 
V2 (F)     +   S/P-o  31 9 
V3 (F)     +  + S/P-o  21 33 
V4 (M)      + + S/P-o  70 7 
V6 (M)   + +    P-o  22 1 +
V12 (M)     +   S  17 10 +
V13 (M)     +   S/P-o  58 10 +
V18 (M)      + + S  72 2 +
V25 (F)       + S  6 13 
V29 (M)     +   S  73 2 +
V31 (M)     +  + S  37 9 
V33 (F)     +   S  51 3 
V40 (M)       + S  41 o1 
V46 (F)      +  S/Seg  o1 37 +
V49 (M)       + S  51 5 
V50 (F) +       S  20 3 +
V52 (M) +  +     S  14 16 +
V14 (M)  +  +    S ATD 58 1 
V20 (M)     +   S AA 20 50 
V21 (M)       + S AA 41 2 
V34 (F)   + +    S ATD 19 40 
V42 (F)  + +     S SLE 51 4 
V43 (F)   +     S ATD 50 8 
V47 (F) + +      S SC 50 8 
V48 (F)    +    S ATD 19 21 
V54 (F)   + +    S ATD 40 10 +
V55 (F)  + +     S ATD 48 10 +
+, positive for antibody reactivity; , negative for antibody reactivity; AA, alopecia areata; ATD, autoimmune thyroid disease; F, female; M, male;
P-o, periorificial; S, symmetrical; SC, scleroderma; SLE, systemic lupus erythematosus; S/Seg, symmetrical with segmental patch.
1 , No autoimmune disease
2Data from Kemp et al., 2002 and Gottumukkala et al., 2006.
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Autoantigens with an association to melanocyte function
were also isolated from the biopanning procedure. The
melanocyte-expressed GTP-binding protein, Rab38, pro-
posed as a regulator of trafficking of melanogenic enzymes
from the trans-Golgi network to melanosomes (Wasmeier
et al., 2006), is expressed at an increased level in vitiligo
melanocytes (Stromberg et al., 2007). Earlier, Rab38 was
reported as an autoantigen in melanoma, but not in patients
with vitiligo (Zippelius et al., 2007). This contrast to our study
may reflect differences in the patients included, such as the
total number of individuals, and in the technique used for Ab
identification. The UCE, which mediates degradation of the
transcriptional regulator of genes involved in melanogenesis,
microphthalmia-associated transcription factor (Xu et al.,
2000), has not been previously characterized as an autoanti-
gen. However, another transcription-related protein that has
been identified as a vitiligo-associated autoantigen, is the
melanocyte-specific transcription factor SOX10 (Hedstrand
et al., 2000).
Further autoantigens of note that were not analyzed in
radioimmunoassays against the panel of vitiligo patient sera
include integrin beta 4 and tyrosine hydroxylase. Integrin
beta 4 is an adhesion molecule vital for the attachment of
epithelial cells to the basal layer of the epidermis (Van der
Neut et al., 1996). How this specific protein relates to
melanocytes has not been reported, but the expression of
several adhesion molecules has been shown to be down-
regulated in vitiligo melanocytes (Stromberg et al., 2007), and
the detachment and transepidermal loss of melanocytes have
been demonstrated in vitiligo (Gauthier et al., 2003). Tyrosine
hydroxylase has already been revealed as an autoantigen in
patients with autoimmune polyglandular syndrome type 1
(Hedstrand et al., 2000), but has not been studied as an
immunological target in vitiligo.
Our earlier studies have detected Abs to several autoanti-
gens in vitiligo patients. Usually, these have been present at a
low frequency, for example, tyrosinase, 11% (Kemp et al.,
1997a); tyrosinase-related protein-1, 5% (Kemp et al.,
1998a); tyrosinase-related protein-2, 5%, (Kemp et al.,
1997b); Pmel17, 5% (Kemp et al., 1998b); transcription
factor SOX10, 3% (Hedstrand et al., 2000); and
Table 7. Details of non-segmental vitiligo patients
without antibody reactivity to the identified
autoantigens
Patient details
Patient
Vitiligo
type
Autoimmune
disease
Age at
vitiligo onset
(years)
Disease
duration
(years)
MCHR1
antibodies1
V5 (F) S  31 12 
V8 (F) S/Seg  10 27 
V9 (F) S  40 36 +
V10 (M) S  56 4 
V15 (F) S  39 9 
V16 (M) S  24 45 
V17 (F) S  70 o1 
V19 (F) S  53 5 
V22 (M) S  13 26 
V23 (M) U  15 28 
V24 (F) S/P-o  21 20 
V26 (F) S  12 23 
V27 (F) S  19 4 
V28 (F) S  39 5 
V30 (F) S  52 1 
V32 (M) S/Seg  37 49 
V35 (F) S  23 o1 
V36 (F) P-o  20 9 
V38 (M) S  31 o1 
V39 (M) S  13 19 
V41 (F) S  39 9 
V45 (F) S  9 5 
V51 (M) S  67 o1 
V11 (M) S ATD 48 1 
V44 (F) S ATD 30 5 +
V53 (F) S ATD 45 6 
, No autoimmune disease; ATD, autoimmune thyroid disease; F, female;
M, male; P-o, periorificial; S, symmetrical; S/Seg, symmetrical with
segmental patch; U, universal.
1Data from Kemp et al., 2002 and Gottumukkala et al., 2006.
Table 8. Comparison of non-segmental vitiligo
patients with and without immunoreactivity to the
identified autoantigens
Patient detail
Patients with
immunoreactivity
(n=27)
Patients with no
immunoreactivity
(n=26)
Sex (M/F) 13/14 9/17
Mean age (range) 45 years (14–76 years) 50 years (19–77 years)
Mean age at onset of
vitiligo (range)
38 years (o1–73 years) 33 years (9–70 years)
Mean disease duration
(range)
12 years (o1–50 years) 14 years (o1–49 years)
Vitiligo subtype:
Symmetrical 21 (78%) 21 (81%)
Symmetrical/
periorificial
4 (15%) 1 (4%)
Symmetrical/
segmental
1 (4%) 2 (8%)
Periorificial 1 (4%) 1 (4%)
Universal 0 (0%) 1 (4%)
Autoimmune disease 10 (37%) 3 (12%)
MCHR1 autoantibodies 10 (37%) 2 (8%)
F, female; M, male; MCHR1, melanin-concentrating hormone receptor 1
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melanin-concentrating hormone receptor 1, 16% (Kemp
et al., 2002). Likewise, the prevalence of Abs to each specific
target identified here was generally low in the population of
patients with non-segmental vitiligo reaching 15% only in the
case of two Ags, UCE and GTP-binding protein, Rab38. The
low prevalence of different Abs may indicate that vitiligo
represents a spectrum of disease pathologies, which lead to a
similar clinical manifestation rather than a disorder with a
single pathogenicity.
Autoimmunity has been suggested to play a role in the
development of non-segmental vitiligo: it is frequently
associated with autoimmune disorders (Taieb, 2000;
Alkhateeb et al., 2003), responds less well to autologous
melanocyte grafting (Gauthier and Surleve-Bazeille, 1992;
Taieb, 2000), and is responsive to treatment with immuno-
suppressive agents (Lepe et al., 2003). In this study, Ab
reactivity to at least one of the identified autoantigens was
detected in 51% (27/53) of patients with non-segmental
vitiligo. Interestingly, no significant difference in the overall
prevalence of immunoreactivity to the cohort of autoantigens
was found between patients with non-segmental vitiligo and
autoimmune disease and those without an associated
autoimmune disorder. However, the majority of Abs against
alpha-enolase, HSP90, and osteopontin were identified in
non-segmental vitiligo patients with autoimmune disease,
whereas the majority of Abs to UCE, translation-initiation
factor 2, GTP-binding protein, Rab38, were revealed as
targets of the humoral immune response in non-segmental
vitiligo patients without an autoimmune disorder. In contrast,
we could not detect Ab reactivity in patients with segmental
vitiligo to any of the autoantigens analyzed, although only
eight samples were available for testing. Notably, it has been
suggested that segmental vitiligo has a different etiology from
the non-segmental type, not involving autoimmune patho-
mechanisms (Taieb, 2000).
Our results indicate that putative vitiligo autoantigens can
be initially identified by phage display technology, including
those proteins with previously demonstrated IgG-binding
properties in association with autoimmune disease and
candidate autoantigens with proposed specific functions in
melanocytes. It is possible that pooling patient IgG samples
for enrichment experiments, as done here, may dilute a
positive autoantibody for which the other pooled IgG are
negative. This may work against the identification of
uncommon but important autoantigens and hence, the
biopanning of single patient IgG samples may be an
alternative in further studies.
Future work will be required to determine whether the Abs
to the specific autoantigens reported here have any patho-
logical significance in vitiligo. Although vitiligo-associated
autoantibodies have been shown to damage melanocytes by
complement-mediated mechanisms and Ab-dependent cel-
lular cytotoxicty (Norris et al., 1988; Gilhar et al., 1995), the
role of the humoral immune response in vitiligo pathogenesis
remains uncertain. In contrast, several studies have under-
lined the role of T lymphocytes in the initiation and
progression of vitiligo (Ogg et al., 1998; Lang et al., 2001;
Palermo et al., 2001; Van den Boorn et al., 2009).
Melanocyte Ag-specific T cells are present in perilesional
vitiligo skin and have cytotoxic activity against pigment cells
(Ogg et al., 1998; Lang et al., 2001; Palermo et al., 2001; Van
den Boorn et al., 2009). Furthermore, perilesional T cells also
have the capacity to destroy melanocytes within skin tissue
itself (Van den Boorn et al., 2009). The Ags recognized by
T cells with anti-melanocyte activity include tyrosinase,
MART-1 (MelanA), and gp100 (Pmel17) (Ogg et al., 1998;
Lang et al., 2001; Palermo et al., 2001; Van den Boorn et al.,
2009). Previously, autoantibodies to tyrosinase (Song et al.,
1994) and Pmel17 (Kemp et al., 1998b) have been detected
in vitiligo patients, and autoantibodies may therefore be
markers of important T-cell responses in vitiligo. With regard
to this, studies to identify T-cell reactivity to the autoantigens
characterized here are needed. Overall, the continued
characterization of anti-melanocyte Ab reactivity in vitiligo
patients is particularly valuable, as this may reveal autoanti-
gens that are also the targets for T cells, which have adverse
effects on pigment cells.
MATERIALS AND METHODS
Patient and control data
Sera from 61 vitiligo patients were used in this study. In 53 patients
(21 male, 32 female; mean age: 48 years with range 14–77 years;
mean disease duration: 13 years with rangeo1–50 years; mean age
at onset: 35 years with rangeo1–73 years), vitiligo was classified as
non-segmental (symmetrical, 42; periorificial, 2; symmetrical/perior-
ificial, 5; universal, 1; symmetrical with segmental patch, 3). Of
these patients, 40 had no other autoimmune disorders and no family
history of autoimmune disease, and 13 had one other autoimmune
disorder: autoimmune thyroid disease 9; alopecia areata, 2; systemic
lupus erythematosus, 1; scleroderma, 1. In eight patients, vitiligo was
classified as segmental (three male, five female; mean age: 33 years
with range 16–58 years; mean disease duration: 2 years with range
o1–4 years; mean age at onset: 33 years with range 14–54 years). Of
these patients, six had no other autoimmune disorders and no family
history of autoimmune disease, and two had alopecia areata. Sera
from 28 healthy individuals (10 male, 18 female; mean age: 34 years
with range 21–59 years) were used as controls. All sera were kept at
20 1C. The study was approved by the South Sheffield Research
Ethics Committee, Sheffield, UK and all patients gave an informed
consent. The study was conducted in accordance with the
Declaration of Helsinki Principles.
IgG biotinylation
Immunoglobulin-G was isolated from the sera of patients using
protein G Sepharose 4 Fast Flow affinity column chromatography
(Amersham Pharmacia Biotech, Uppsala, Sweden). Eluted IgG
fractions were dialysed extensively against phosphate-buffered
saline (PBS; pH 7.4; Sigma, Poole, UK) and concentrated using an
Amicon Concentrator (Amicon, Beverley, MA). The concentrated
IgG was filter-sterilized with a Millex Filter Unit (Millipore, Bedford,
MA) and the final concentration measured by photometry at 280 nm.
Samples were stored at a concentration of 10mgml1 at 20 1C.
Biotinylation of the IgG was performed using EZ-Link Sulfo-NHS-LC-
LC-Biotin (Pierce, Rockford, IL), according to the manufacturer’s
protocol. All biotinylated IgG samples were stored at a concentration
of 2mgml1 at 4 1C.
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Melanocyte cDNA phage display library
Construction of the melanocyte cDNA phage display library in
vector pJuFo-Sfi was described previously (Kemp et al., 2002). The
library was stored in PBS at 80 1C.
Biopanning experiments
In biopanning experiments, 15-ml aliquots of biotinylated IgG were
incubated with 200 mg of Dynabeads M-280 Streptavidin (Dynal
Biotech, Oslo, Norway), prepared according to the manufacturer in
235ml of sterile water, and incubated at 4 1C for 30minutes on a
rotating platform to permit Ab–bead binding. To block any non-
specific phage particles from binding to the beads later in the
procedure, 300 ml of 2% (w/v) dried milk powder in PBS containing
10% (w/v) glycerol were added to the bead–IgG suspension and
incubation continued for 1 hour at 4 1C. The bead–IgG complexes
were separated from the blocking buffer using a Dynal Magnetic
Particle Concentrator (Dynal Biotech), washed twice and finally
resuspended in 150ml of PBS/0.05% (w/v) Tween 20 before the
addition of a 100-ml sample of phage display library. The suspension
was then incubated overnight at 4 1C to allow interaction of the
Ab–bead complexes with peptides displayed on the surface of the
phage particles. The bead–IgG complexes were washed extensively
with PBS/0.05% (w/v) Tween 20 to remove any unbound phage
particles. Bound phage particles were eluted from the bead–IgG
complexes with 150 ml of 100mM HCl (adjusted to pH 2.2 with solid
glycine) and the beads magnetically separated from the supernatant,
which was neutralized using 9 ml of 2 M Tris. The phage particle
suspension was subsequently used to infect 2ml of exponentially
growing E. coli XL1-Blue (Stratagene) for 15minutes at room
temperature. Aliquots of the infected cells were then plated onto
selective medium to allow the recovery of individual bacterial
clones for analysis and to determine the numbers of phage particles
eluted.
To generate a phage display library for a further round of
selection, the infected E. coli XL1-Blue culture was superinfected
with 1 1012 plaque-forming units of VCMS13 helper phage
(Stratagene) at room temperature for 30minutes. The culture was
subsequently transferred to 100ml of LB (Luria–Bertani) medium
(Sambrook et al., 1989) supplemented with 50 mgml1 ampicillin,
10 mgml1 tetracycline, and 10 mgml1 kanamycin. After
overnight incubation at 37 1C, the culture was centrifuged and
phage particles precipitated from the supernatant with 0.2 volumes
of 20% (w/v) polyethylene glycol 4000/2.5M NaCl. The phage
particles were resuspended in 2–3ml of PBS and stored at 201C.
This first round library enriched in phage particles displaying IgG-
binding peptides was used in a second round of selective
enrichment, as detailed above. In all, five rounds of biopanning
were undertaken.
Throughout, phage particle titers were determined by infecting
log-phase E. coli XL1-Blue with an aliquot of phage display library
and then plating out samples onto LB agar containing 50 mgml1
ampicillin and 10 mgml1 tetracycline.
For analysis, individual bacterial clones were cultured and
phagemid DNA prepared using a Wizard Minipreps DNA Purifica-
tion System (Promega, Southampton, UK). To confirm the presence
of a cDNA insert, phagemid DNA (50ng samples) was subjected to
36 cycles of PCR amplification in a DNA Thermal Cycler (Perkin-
Elmer/Cetus, Norwalk, CT) using previously detailed reaction
conditions (Kemp et al., 2001) with primers 1192 (50-
CCGCTGGATTGTTATTACTCGCTG-30) and 1500 (50-TGCAAGGC
GATTAAGTTGGGTAAC-30) (Life Technologies, Paisley, UK), which
flank the SfiI cloning site in pJuFo-Sfi (Kemp et al., 2002). The PCR
amplification products were analyzed by agarose gel electrophoresis
(Sambrook et al., 1989) and purified according to a Wizard PCR
Preps DNA Purification System (Promega). Sequencing of
PCR amplification products with primer 1192 was carried out
using a BigDye Terminator Version 3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA) and an ABI 3730 capillary
sequencer (Applied Biosystems). The cDNA sequences were
compared with international databases using the BLAST network
service of the National Centre for Biotechnology Information
(Bethesda, MD).
Cloning of putative autoantigens
Total melanocyte RNA (1mg) was used to prepare cDNA in a 30-ml
reaction containing 10mM dithiothreitol, 1mM dNTPs (Promega),
250 ng random primers (Promega), 600U M-MLV reverse transcrip-
tase (Promega) and 1 M-MLV reverse transcriptase buffer
(Promega). The cDNA was subjected to PCR amplification using
conditions as described previously (Kemp et al., 2001) with
Ag-specific primers (Supplementary Table S1). Restriction sites
for EcoRI and XbaI were incorporated into the forward and reverse
primers, respectively, to allow subcloning of the PCR amplification
product into pcDNA3 (Invitrogen, Abingdon, UK) and subsequent
expression of the cDNA from the T7 promoter in the vector.
Recombinant plasmids (Supplementary Table S1) were purified
with a Qiagen Plasmid Maxi Kit (Qiagen, Crawley, UK) and
verified by sequencing as above with T7 and SP6 primers
(Promega).
Radioimmunoassays assays
In vitro translation of putative autoantigens cloned in pcDNA3
(Supplementary Table S1) was performed according to a TnT T7
Coupled Reticulocyte Lysate System (Promega) with translation-
grade [35S]-methionine (1000Cimmol1; 10mCiml1; Amersham
Pharmacia Biotech, Little Chalfont, UK). SDS-PAGE of in vitro
translated Ags was carried out in 10% (w/v) polyacrylamide gels
using standard protocols (Sambrook et al., 1989). Gels were
processed and autoradiographed at 70 1C, as detailed elsewhere
(Kemp et al., 1998a).
Assays were executed as previously detailed (Kemp et al., 1998a)
with serum at a final dilution of 1:100 and with each sample in
duplicates. An Ab index for each serum tested in the radio-
immunoassays was calculated as counts per minute immuno-
precipitated by tested serum/mean counts per minute immunopre-
cipitated by 28 healthy control sera. Each serum was tested in at least
two experiments and the mean Ab index was calculated. The upper
limit of normal for the assay was calculated using the mean Ab
indexþ 3 SD of the population of 28 healthy individuals. Any serum
with an Ab index above the upper limit of normal was designated as
positive for Ab reactivity.
Statistical analysis
The frequency of Abs was compared between patients and controls
using Fisher’s exact test for 2 2 contingency tables. P-valueso0.05
(two-tailed) were regarded as significant.
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